Table 3.

Difference in anti-SARS-CoV2 anti-spike IgG (BAU/mL), geometric means (95%CI) at days 14 and 28 from baseline, n = 399.

		Increase in titer at day 14	p-value	Increase in titer at day 28	p-value
Gender	Male (n = 101)	1403.3 (1036.3–1900.2)	0.337	905.8 (682.1–1202.8)	0.271
	Female (n = 298)	1169.6 (965.3–1417.2)		744.4 (620.7–892.7)
Local erythema	Yes (n = 23)	3275.7 (2493.0–4304.1)	<0.001∗	1828.4 (1401.7–2384.9)	<0.001∗
	No (n = 376)	1153.3 (973.4–1366.3)		742.7 (632.7–871.8)
Local swelling	Yes (n = 41)	3015.3 (2413.0–3767.9)	<0.001∗	1711.6 (1389.5–2108.4)	<0.001∗
	No (n = 358)	1104.6 (926.3–1317.1)		716.5 (606.7–846.2)
Local pain	Yes (n = 326)	1562.5 (1330.8–1834.6)	<0.001∗	940.6 (803.4–1101.2)	<0.001∗
	No (n = 74)	406.9 (259.0–639.4)		330.6 (219.2–498.7)
Fever ≥ 38° C	Yes (n = 136)	2706.0 (2309.2–3171.0)	<0.001∗	1576.0(1353.9–1834.5)	<0.001∗
	No (n = 263)	815.5 (657.0–1012.3)		542.9 (441.8–667.1)
Arthralgia/arthritis	Yes (n = 31)	3038.0 (2440.4–3782.0)	<0.001∗	1734.9 (1415.1–2127.0)	<0.001∗
	No (n = 368)	1134.5 (954.5–1348.4)		731.3 (621.0–861.2)
Nausea/vomit	Yes (n = 22)	2443.7 (1402.1–4259.2)	0.043∗	1428.8 (855.5–2386.1)	0.060
	No (n = 377)	1176.5 (994.4–1391.8)		755.4 (644.4–885.6)
Chills	Yes (n = 158)	2149.6 (1757.8–2628.7)	<0.001∗	1295.5 (1073.8–1565.5)	<0.001∗
	No (n = 241)	845.9 (676.9–1057.2)		561.7 (454.4–694.3)
Headache	Yes (n = 179)	1617.5 (1313.9–1991.3)	0.002∗	992.9 (820.8–1201.1)	0.004∗
	No (n = 220)	976.0 (769.3–1238.2)		644.3 (512.6–809.9)
Myalgia	Yes (n = 292)	1734.2 (1474.3–2039.9)	<0.001∗	1082.2 (934.1–1253.9)	<0.001∗
	No (n = 107)	470.2 (328.5–672.9)		318.4 (222.1–456.3)
Fatigue	Yes (n = 299)	1577.4 (1330.5–1870.1)	<0.001∗	994.2 (849.8–1163.3)	<0.001∗
	No (n = 100)	576.6 (399.9–831.4)		381.3 (265.9–546.8)
Systemic Rash	Yes (n = 30)	1563.3 (857.7–2849.3)	0.399	947.7 (576.6–1557.7)	0.481
	No (n = 369)	1200.9 (1014.1–1422.0)		770.6 (656.0–905.2)

IgG: immunoglobulin G, BAU/mL: binding antibody units/mL, CI: confidence interval.